Publications by authors named "M Yaga"
CAR-NK cells derived from cord blood originate mainly from CD56CD7CD34HLA-DRLin NK progenitor cells.
Mol Ther Methods Clin Dev
December 2024
Cord blood (CB)-derived chimeric antigen receptor (CAR)-natural killer (NK) cells targeting CD19 have been shown to be effective against B cell malignancies. While human CD56 NK cells can be expanded , NK cells can also be differentiated from hematopoietic progenitor cells. It is still unclear whether CAR-NK cells originate from mature NK cells or NK progenitor cells in CB.
View Article and Find Full Text PDFArticle Synopsis
- Glioblastoma multiforme (GBM) is a highly aggressive brain tumor that urgently needs new therapies; CAR T cell therapy has shown promise but is costly and time-intensive.
- Researchers are exploring CAR-transduced natural killer (NK) cells as an "off-the-shelf" immunotherapy alternative, which can avoid complications like graft-versus-host disease.
- Both CAR-T and CAR-NK cells targeting the B7-H3 protein demonstrated significant effectiveness in killing GBM cells in lab tests and in animal models, suggesting they could be viable treatment options for this aggressive cancer.
Article Synopsis
- CAR T cell therapy has shown success in treating blood cancers but struggles with solid tumors like non-small cell lung cancer (NSCLC) due to a lack of specific cell surface targets.
- Researchers identified that CD98 heavy chain protein is overexpressed in NSCLC cells and could serve as a target for CAR T cells.
- A specific monoclonal antibody called R8H283, which reacts selectively with NSCLC cells without impacting normal tissues, led to the development of CAR T cells that demonstrated significant anti-tumor effects in model studies.
Rationale: Extracorporeal membrane oxygenation (ECMO) is the last trump card for severe respiratory failure. The main complications of ECMO are bleeding and thrombosis, both of which can be life-threatening. Large blood clots can cause central airway obstruction (CAO) during ECMO, and CAO should be removed as soon as possible because of asphyxiation.
View Article and Find Full Text PDFProgressive pulmonary fibrosis (PPF), defined as the worsening of various interstitial lung diseases (ILDs), currently lacks useful biomarkers. To identify novel biomarkers for early detection of patients at risk of PPF, we performed a proteomic analysis of serum extracellular vesicles (EVs). Notably, the identified candidate biomarkers were enriched for lung-derived proteins participating in fibrosis-related pathways.
View Article and Find Full Text PDF